Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-1.70 Insider Own0.80% Shs Outstand151.65M Perf Week-7.01%
Market Cap8.41B Forward P/E164.57 EPS next Y0.34 Insider Trans-25.85% Shs Float150.70M Perf Month1.87%
Income-256.70M PEG- EPS next Q0.04 Inst Own97.80% Short Float3.73% Perf Quarter26.42%
Sales695.30M P/S12.10 EPS this Y-635.70% Inst Trans-0.16% Short Ratio4.71 Perf Half Y16.56%
Book/sh7.98 P/B6.95 EPS next Y270.00% ROA-14.40% Target Price64.25 Perf Year-14.23%
Cash/sh3.62 P/C15.31 EPS next 5Y- ROE-20.40% 52W Range27.14 - 69.65 Perf YTD-0.22%
Dividend- P/FCF- EPS past 5Y-26.20% ROI-13.70% 52W High-20.37% Beta2.14
Dividend %- Quick Ratio4.00 Sales past 5Y27.50% Gross Margin81.00% 52W Low104.35% ATR2.01
Employees1500 Current Ratio4.20 Sales Q/Q18.00% Oper. Margin-36.30% RSI (14)44.29 Volatility4.64% 3.41%
OptionableYes Debt/Eq0.24 EPS Q/Q23.70% Profit Margin-36.90% Rel Volume0.62 Prev Close54.65
ShortableYes LT Debt/Eq0.23 EarningsFeb 01 BMO Payout- Avg Volume1.19M Price55.46
Recom2.30 SMA20-2.56% SMA50-2.15% SMA20016.16% Volume743,069 Change1.48%
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Oct-04-16Resumed Leerink Partners Outperform $57
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Oct-07-15Reiterated Barclays Overweight $77 → $79
Sep-01-15Upgrade Morgan Stanley Underweight → Overweight
Jun-09-15Initiated Guggenheim Neutral
May-21-15Initiated Barclays Overweight $74
Jan-08-15Reiterated Mizuho Buy $72 → $81
Jul-31-14Reiterated Mizuho Buy $61 → $59
Apr-10-14Upgrade Mizuho Neutral → Buy $55 → $61
Apr-09-14Reiterated MKM Partners Sell $32 → $35
Feb-28-14Reiterated UBS Neutral $42 → $53
Feb-28-14Reiterated MKM Partners Sell $26 → $32
Feb-28-14Reiterated Mizuho Neutral $33 → $56
Dec-05-13Downgrade UBS Buy → Neutral $37 → $42
Nov-01-13Reiterated Mizuho Neutral $30 → $33
Jan-13-17 03:33PM  Mott Capital Says Netflix (NFLX) At Forefront of Paradigm Shift, Talks Disney, Hain, NXPI Deal, More at Insider Monkey
Jan-11-17 08:15AM  Blog Coverage Valeant Sells-Off Its Skin Care Brands to L'Oreal Accesswire -6.65%
Jan-05-17 02:44PM  Top Biotech Picks: "The Strong Will Survive And Thrive" at Barrons.com
10:35AM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : January 5, 2017
Jan-04-17 08:07AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : January 4, 2017 +6.77%
Jan-03-17 04:00PM  Alkermes Corporate Presentation to be Webcast at the 35th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-21-16 11:56AM  ETFs with exposure to Alkermes Plc : December 21, 2016
Dec-08-16 02:40AM  Alkermes Plc (ALKS): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-05-16 03:00PM  CERC: CERC-501 Not Successful in Nicotine Withdrawal; Preparing for Phase 2/3 Study of CERC-501 in MDD
Dec-02-16 04:31PM  ALKERMES PLC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-30-16 12:30PM  CERC: CERC-301 Fails to Show Benefit in MDD in Phase 2 Clinical Trial; Attention Now Turns to CERC-501
Nov-22-16 08:53AM  Acorda Stops Post-Stroke Development Program on Ampyra
Nov-18-16 04:49PM  Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Points Bet on Healthcare Sector Paid Off? at Insider Monkey
Nov-15-16 03:44PM  Alkermes (ALKS) CEO Pops Says Biotech Stocks 'Recovered Quite a Bit' Post-Election
02:36PM  Drug pricing pressure
Nov-10-16 12:00PM  ETFs with exposure to Alkermes Plc : November 10, 2016
Nov-09-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Jefferies 2016 London Healthcare Conference Business Wire +7.73%
10:01AM  Alkermes Plc :ALKS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
Nov-07-16 02:55PM  Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward at Motley Fool
Nov-05-16 01:04PM  ALKERMES PLC. Financials
Nov-03-16 09:00AM  Alkermes (ALKS) Q3 Loss in Line, Sales Miss; '16 View Intact
07:00AM  ALKERMES Inspiration Grants Awarded to Support People Affected by Mental Health and Substance Use Disorders Business Wire
Nov-02-16 01:41PM  Edited Transcript of ALKS earnings conference call or presentation 2-Nov-16 12:30pm GMT
08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today
07:32AM  Alkermes reports 3Q loss
07:08AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:07AM  Q3 2016 Alkermes Plc Earnings Release - Before Market Open
07:00AM  Alkermes plc Reports Third Quarter 2016 Financial Results Business Wire
Nov-01-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Credit Suisse 25th Annual Healthcare Conference Business Wire
08:20AM  Drug Stocks to Watch for Earnings on Nov 2; AGN, ZTS & More
Oct-27-16 06:00AM  Jim Cramer's Top Takeaways: Norfolk Southern, Apple, Snap-On
Oct-26-16 07:16PM  Cramer Remix: Who is right and wrong when it comes to Apple at CNBC
04:00PM  Alkermes to Host Conference Call to Discuss Third Quarter 2016 Financial Results Business Wire
09:43AM  Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex Q3 Results Miss Estimates
Oct-25-16 10:10AM  Hot Tech and Biotech Companies Highlight Jefferies Stocks to Buy at 24/7 Wall St.
Oct-24-16 04:20PM  Alkermes, Lundbeck Cannibalize Johnson & Johnson's Schizophrenia Sales
09:59AM  What To Watch From The Upcoming Cerecor Inc (CERC) Release at Insider Monkey
09:30AM  Alkermes Depression Drug Shows Good Results (ALKS) at Investopedia
08:18AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : October 24, 2016
07:55AM  Are Alkermes Analysts Chasing This Story Too Hard, or Is It Just a Start? at 24/7 Wall St.
Oct-22-16 01:26PM  Reynolds American, Inc. (RAI), MGP Ingredients Inc (MGPI), and More: Heres What Analysts Had To Say About These Stocks in the Spotlight at Insider Monkey
Oct-21-16 06:45PM  [$$] Clinical Development News, Oct. 17-21 at The Wall Street Journal +27.83%
04:15PM  Alkermes stock surges on depression drug's success in late-stage trial at CNBC
04:09PM  Alkermes Hits 9-Month High On 'Blockbuster Potential' Antidepressant
02:30PM  Alkermes, Inc. -- Moody's Alkermes' FORWARD-5 trial is credit positive at Moody's
01:32PM  Why Alkermes PLC Skyrocketed Today at Motley Fool
12:52PM  Alkermes (ALKS) Stock Soars on Trial Results, Upgrades
09:25AM  Alkermes Depression Candidate Positive in Phase III Study
09:09AM  The Market In 5 Minutes: Big Earnings In Focus And A Tobacco Giant In The Making
09:07AM  Early movers: GE, HON, STI, COH, MSFT, RAI, AMD, SKX, SLB & more at CNBC
08:30AM  Why Traders Are Buzzing About Qualcomm, NXP, Alkermes, Cerecor, and More at Insider Monkey
07:45AM  Why Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma at 24/7 Wall St.
07:07AM  Alkermes' depression drug trial win could be a test case for the FDA at bizjournals.com
06:04AM  Alkermes upgraded by JP Morgan
Oct-20-16 05:18PM  [$$] Alkermes Shares Surge at The Wall Street Journal
05:04PM  After-hours buzz: MSFT, ALKS, PYPL and more at CNBC
05:00PM  Alkermes Plc Conference Call to Discuss FORWARD-5 ALKS 5461 Data scheduled for 5:00 pm ET today
04:41PM  Alkermes Soars As Antidepressant Finally Delivers At Trials
04:25PM  Alkermes shares soar more than 40% after depression drug results at MarketWatch
04:24PM  Depression drug by Walthams Alkermes aces late-stage trial at bizjournals.com
04:15PM  Alkermes Surges as Depression Drug Hits Goal in Late-Stage Trial
04:15PM  Alkermes Surges as Depression Drug Hits Goal in Late Trial at Bloomberg
04:06PM  Alkermes Depression Drug Finds Success on Third Study Attempt
04:04PM  Alkermes releases positive data on depression data
04:03PM  ALKERMES PLC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
04:00PM  Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Business Wire
Oct-13-16 04:51PM  ALKERMES PLC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Oct-04-16 06:16PM  Alkermes Commences Metabolic Study on Schizophrenia Drug
Oct-03-16 10:34AM  Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating
07:00AM  Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia Business Wire
Sep-30-16 08:30AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : September 30, 2016
Sep-27-16 10:39AM  Jim Cramer -- Gilead Needs to Make an Acquisition
09:54AM  Cramer's Stop Trading: GILD, GWPH & ALKS
Sep-23-16 04:33PM  Virgin Extends Drop As Alaska Air Merger Review Grows Longer
Sep-20-16 04:14PM  ALKERMES PLC. Files SEC form 8-K/A, Change in Directors or Principal Officers
Sep-19-16 04:00PM  Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Business Wire
Sep-15-16 11:13AM  Moving Average Crossover Alert: Alkermes (ALKS)
Sep-12-16 07:00AM  Alkermes Launches Competitive Grants Program to Support People Affected by Mental Health and Substance Use Disorders Business Wire +5.20%
Sep-09-16 01:51PM  Alkermes Plc Value Analysis (NASDAQ:ALKS) : September 9, 2016
Sep-08-16 08:03AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : September 8, 2016
Sep-06-16 04:00PM  Alkermes Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Business Wire
Aug-25-16 10:00AM  ETFs with exposure to Alkermes Plc : August 25, 2016
Aug-24-16 08:03AM  Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : August 24, 2016
Aug-15-16 10:00AM  Want a Dash for Trash? Why Not Look at Alkermes
Aug-11-16 08:14AM  Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : August 11, 2016
Aug-08-16 07:00AM  Alkermes Submits Supplemental New Drug Application to FDA for Two-Month Dosing Option of ARISTADA┬« for Treatment of Schizophrenia Business Wire
Aug-04-16 02:36PM  ETFs with exposure to Alkermes Plc : August 4, 2016
Aug-03-16 12:29PM  Alkermes Plc :ALKS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016
Jul-29-16 12:44PM  ALKERMES PLC. Files SEC form 8-K, Other Events
11:06AM  Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook
Jul-28-16 08:30AM  Alkermes Plc Earnings Call scheduled for 8:30 am ET today -7.05%
08:20AM  Alkermes reports 2Q loss
07:07AM  Q2 2016 Alkermes Plc Earnings Release - Before Market Open
07:06AM  ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:00AM  Alkermes plc Reports Second Quarter 2016 Financial Results Business Wire
Jul-27-16 03:00PM  A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)s Topline Triumph at Insider Monkey
06:00AM  Jim Cramer's Top Takeaways: Acacia Communications, KeyCorp, Alkermes
Jul-26-16 07:09PM  Cramer Remix: It's time for Jack Dorsey to make a choice at CNBC
03:00PM  [$$] Three Biotech Q2 Reports Hold Potential at Barrons.com
Jul-22-16 07:53PM  Whats Been Beating down the Fidelity Growth Company Fund in 2016?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; INVEGA TRINZA for the treatment of schizophrenia used in people who have been treated with INVEGA SUSTENNA; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to improve walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in a Phase III study for the treatment of major depressive disorder; ALKS 3831, which is in a Phase II study to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in a Phase I study to treat multiple sclerosis; ALKS 6428, which is in a phase III study to help physicians transition patients from physical dependence on opioids to antagonist therapy; Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I study for the treatment of schizophrenia; ALKS 7119 that is in a Phase I study for the treatment of various central nervous system diseases; RDB 1450, a proprietary investigational biologic cancer immunotherapy product that is in pre-clinical stage. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Janssen Pharmaceutica N.V.; AstraZeneca plc; and Acorda Therapeutics, Inc. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 09Option Exercise17.305479,46334,662Jan 10 05:08 PM
Cooke ShanePresident, Alkermes plcJan 09Option Exercise14.605508,03064,494Jan 10 05:10 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 09Sale60.2754732,96834,115Jan 10 05:08 PM
Cooke ShanePresident, Alkermes plcJan 09Sale60.2755033,14963,944Jan 10 05:10 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 06Option Exercise17.306,653115,09740,768Jan 06 07:32 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 06Option Exercise18.112,10038,02154,740Jan 06 06:28 PM
Cooke ShanePresident, Alkermes plcJan 06Option Exercise14.606,60796,46270,551Jan 06 06:36 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 06Sale60.076,653399,64334,115Jan 06 07:32 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 06Sale60.122,100126,24652,640Jan 06 06:28 PM
Cooke ShanePresident, Alkermes plcJan 06Sale60.076,607396,91063,944Jan 06 06:36 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 05Option Exercise17.303005,19034,415Jan 06 07:32 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 05Option Exercise18.114007,24253,040Jan 06 06:28 PM
Cooke ShanePresident, Alkermes plcJan 05Option Exercise14.603004,38064,244Jan 06 06:36 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 05Sale60.0930018,02634,115Jan 06 07:32 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 05Sale60.0840024,03152,640Jan 06 06:28 PM
Cooke ShanePresident, Alkermes plcJan 05Sale60.1030018,03163,944Jan 06 06:36 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 04Option Exercise17.302,50043,25036,615Jan 06 07:32 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 04Option Exercise18.117,500135,78860,140Jan 06 06:28 PM
Cooke ShanePresident, Alkermes plcJan 04Option Exercise14.602,54337,12866,487Jan 06 06:36 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncJan 04Sale60.012,500150,01834,115Jan 06 07:32 PM
BREYER ROBERT ADirectorJan 04Sale60.004,000240,00011,156Jan 06 05:43 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jan 04Sale59.227,500444,14852,640Jan 06 06:28 PM
Cooke ShanePresident, Alkermes plcJan 04Sale60.012,543152,60763,944Jan 06 06:36 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Jan 03Option Exercise15.772,50039,42027,457Jan 04 05:26 PM
MITCHELL PAUL JDirectorJan 03Option Exercise11.441,50017,1609,500Jan 04 05:34 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Jan 03Sale55.402,500138,50024,957Jan 04 05:26 PM
MITCHELL PAUL JDirectorJan 03Sale55.401,50083,1008,000Jan 04 05:34 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Dec 16Option Exercise16.554,76878,91025,355Dec 19 05:06 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Dec 16Sale57.734,768275,26520,587Dec 19 05:06 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Dec 15Option Exercise16.5516,690276,22037,277Dec 19 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Dec 15Option Exercise18.115,00090,52557,640Dec 15 07:00 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Dec 15Sale57.6216,690961,72020,587Dec 19 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Dec 15Sale55.995,000279,96352,640Dec 15 07:00 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSDec 14Option Exercise13.1725,000329,350137,342Dec 15 06:54 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSDec 14Sale54.7325,0001,368,133112,342Dec 15 06:54 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Dec 12Option Exercise17.0715,000256,02569,623Dec 13 06:04 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Dec 12Sale55.1516,983936,63152,640Dec 13 06:04 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 08Option Exercise14.384,14559,60542,832Dec 08 05:58 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 08Sale55.424,145229,70738,687Dec 08 05:58 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 07Option Exercise14.385,00071,90043,687Dec 08 05:58 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSDec 07Option Exercise14.1823,731336,409136,073Dec 08 06:24 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 07Sale56.615,000283,04838,687Dec 08 05:58 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSDec 07Sale56.2823,7311,335,632112,342Dec 08 06:24 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 06Option Exercise14.385,00071,90043,687Dec 08 05:58 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 06Sale56.245,000281,21138,687Dec 08 05:58 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 01Option Exercise14.3815,000215,70053,687Dec 02 05:40 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSDec 01Sale56.1315,000841,98938,687Dec 02 05:40 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 30Option Exercise14.3810,000143,800165,659Nov 30 05:16 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 30Sale57.5110,000575,083155,659Nov 30 05:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 29Option Exercise14.3830,000431,400638,962Nov 30 05:14 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 29Sale56.9830,0001,709,469608,962Nov 30 05:14 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 22Option Exercise14.3830,000431,400638,962Nov 22 05:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 22Sale58.6630,0001,759,936608,962Nov 22 05:05 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSNov 18Option Exercise16.556,04299,99595,474Nov 21 06:02 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 16Option Exercise14.3810,000143,800165,659Nov 17 06:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 16Sale58.5910,000585,901155,659Nov 17 06:10 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 15Option Exercise14.3830,000431,400638,962Nov 17 06:07 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 15Sale58.8230,0001,764,525608,962Nov 17 06:07 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Nov 11Option Exercise13.883,44347,78624,957Nov 14 05:53 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncNov 10Option Exercise17.305,78099,99435,807Nov 14 05:49 PM
BREYER ROBERT ADirectorNov 10Sale60.0020,0001,200,00015,156Nov 14 05:46 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 09Option Exercise14.3810,000143,800165,659Nov 10 05:28 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Nov 09Sale56.2210,000562,183155,659Nov 10 05:28 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Option Exercise14.3830,000431,400638,962Nov 10 05:18 PM
POPS RICHARD FDirector and CEO, Alkermes plcNov 08Sale53.2830,0001,598,462608,962Nov 10 05:18 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Nov 07Option Exercise11.748,51799,99056,475Nov 08 05:06 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncOct 05Option Exercise0.005,000031,650Oct 06 09:15 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Oct 05Option Exercise0.005,000022,803Oct 06 09:14 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Oct 05Option Exercise0.005,0000158,012Oct 06 09:09 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Oct 05Option Exercise0.001,600022,034Oct 06 09:07 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSOct 05Option Exercise0.005,000091,785Oct 06 09:04 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Oct 05Option Exercise0.005,000050,311Oct 06 09:01 PM
Cooke ShanePresident, Alkermes plcOct 05Option Exercise0.007,500067,844Oct 06 08:59 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Oct 05Option Exercise0.001,600023,827Oct 06 08:57 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO Alks Inc; Sec ALKSOct 05Option Exercise0.005,000041,540Oct 06 08:55 PM
POPS RICHARD FDirector and CEO, Alkermes plcOct 05Option Exercise0.0020,0000618,372Oct 07 04:02 PM
MITCHELL PAUL JDirectorOct 04Option Exercise18.292,00036,58010,000Oct 04 05:25 PM
MITCHELL PAUL JDirectorOct 04Sale47.422,00094,8408,000Oct 04 05:25 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 22Option Exercise18.113,83469,41549,145Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 22Sale50.843,834194,92645,311Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 21Option Exercise18.111,16621,11046,477Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 21Sale50.811,16659,24245,311Sep 22 05:01 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 16Option Exercise18.115,00090,52550,311Sep 19 05:21 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 16Sale48.875,000244,33145,311Sep 19 05:21 PM
MITCHELL PAUL JDirectorSep 06Option Exercise18.292,00036,58010,000Sep 07 05:13 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Sep 06Option Exercise14.382,38234,25322,816Sep 07 05:16 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 06Option Exercise18.1110,000181,05055,311Sep 07 05:31 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Sep 06Sale46.0210,000460,23545,311Sep 07 05:31 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Sep 06Sale45.9229,9761,376,62722,227Sep 07 05:27 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Sep 06Sale45.922,382109,37820,434Sep 07 05:16 PM
MITCHELL PAUL JDirectorSep 06Sale45.922,00091,8348,000Sep 07 05:13 PM
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc.Aug 05Option Exercise16.556,04299,99517,803Aug 08 05:09 PM
MITCHELL PAUL JDirectorAug 04Option Exercise18.292,00036,58010,000Aug 05 05:04 PM
MITCHELL PAUL JDirectorAug 04Sale49.482,00098,9668,000Aug 05 05:04 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 27Option Exercise16.5534,399569,30379,710Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 27Sale51.9534,3991,787,07645,311Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 26Option Exercise16.5580013,24046,111Jul 28 05:06 PM
Ehrich ElliotEVP, R&D & CMO, Alkermes, Inc.Jul 26Sale51.8280041,45545,311Jul 28 05:06 PM
MITCHELL PAUL JDirectorJul 05Option Exercise18.292,00036,58010,000Jul 06 05:17 PM
MITCHELL PAUL JDirectorJul 05Sale45.812,00091,6208,000Jul 06 05:17 PM